Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening

Richard J. Rickles, Winnie F. Tam, Thomas P. Giordano, III, Laura T. Pierce, Melissa Farwell, Douglas W. McMillin, Antoaneta Necheva, David Crowe, Mei Chen, William Avery, Vikram Kansra, Steffan T. Nawrocki, Jennifer S. Carew, Francis J. Giles, Constantine S. Mitsiades, Alexis A. Borisy, Kenneth C. Anderson, Margaret S. Lee

Mol Cancer Ther (2012) 11 (7): 1432–1442.

https://doi.org/10.1158/1535-7163.MCT-11-0925

Published: 05 July 2012

View articletitled, Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening

Includes: Supplementary data

Journal Articles

Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma

Douglas W. McMillin, Hannah M. Jacobs, Jake E. Delmore, Leutz Buon, Zachary R. Hunter, Val Monrose, Jie Yu, Peter G. Smith, Paul G. Richardson, Kenneth C. Anderson, Steven P. Treon, Andrew L. Kung, Constantine S. Mitsiades

Mol Cancer Ther (2012) 11 (4): 942–951.

https://doi.org/10.1158/1535-7163.MCT-11-0563

Published: 08 April 2012

View articletitled, Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma

Includes: Supplementary data

Journal Articles

Abstract A237: The transcriptional signature of kinases inhibited by the multitargeted kinase inhibitor AS703569 is associated with inferior clinical outcome in multiple myeloma (MM), with promising anti‐MM activity of AS703569 demonstrated in preclinical studies in vitro and in vivo

Jake Delmore, David N. Cervi, Douglas W. McMillin, Efstathios Kastritis, Jana Jakubikova, Steffen Klippel, Joseph M. Negri, Buon Leutz, Jacob Laubach, Luca Rastelli, Ann Clark, Samantha Sarno, Paul G. Richardson, Kenneth C. Anderson, Mitsiades Constantine

Mol Cancer Ther (2009) 8 (12_Supplement): A237.

https://doi.org/10.1158/1535-7163.TARG-09-A237

Published: 10 December 2009

View articletitled, Abstract A237: The transcriptional signature of kinases inhibited by the multitargeted kinase inhibitor AS703569 is associated with inferior clinical outcome in multiple myeloma (MM), with promising anti‐MM activity of AS703569 demonstrated in preclinical studies in vitro and in vivo

Journal Articles

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

Ellen Weisberg, Renee D. Wright, Douglas W. McMillin, Constantine Mitsiades, Arghya Ray, Rosemary Barrett, Sophia Adamia, Richard Stone, Ilene Galinsky, Andrew L. Kung, James D. Griffin

Mol Cancer Ther (2008) 7 (5): 1121–1129.

https://doi.org/10.1158/1535-7163.MCT-07-2331

Published: 15 May 2008

View articletitled, Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

Includes: Supplementary data

Journal Articles

Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

Ellen Weisberg, Andrew L. Kung, Renee D. Wright, Daisy Moreno, Laurie Catley, Arghya Ray, Leigh Zawel, Mary Tran, Jan Cools, Gary Gilliland, Constantine Mitsiades, Douglas W. McMillin, Jingrui Jiang, Elizabeth Hall-Meyers, James D. Griffin

Mol Cancer Ther (2007) 6 (7): 1951–1961.

https://doi.org/10.1158/1535-7163.MCT-06-0810

Published: 09 July 2007

View articletitled, Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

Includes: Supplementary data

Journal Articles

Targeting BRAF^V600E in thyroid carcinoma: therapeutic implications

Constantine S. Mitsiades, Joseph Negri, Ciaran McMullan, Douglas W. McMillin, Elias Sozopoulos, Galinos Fanourakis, Gerassimos Voutsinas, Sophia Tseleni-Balafouta, Vassiliki Poulaki, David Batt, Nicholas Mitsiades

Mol Cancer Ther (2007) 6 (3): 1070–1078.

https://doi.org/10.1158/1535-7163.MCT-06-0449

Published: 15 March 2007

View articletitled, Targeting BRAFV600E in thyroid carcinoma: therapeutic implications

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening

Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma

Abstract A237: The transcriptional signature of kinases inhibited by the multitargeted kinase inhibitor AS703569 is associated with inferior clinical outcome in multiple myeloma (MM), with promising anti‐MM activity of AS703569 demonstrated in preclinical studies in vitro and in vivo

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

Targeting BRAF^V600E in thyroid carcinoma: therapeutic implications

Email alerts

AACR Journals

Update search

Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening

Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma

Abstract A237: The transcriptional signature of kinases inhibited by the multitargeted kinase inhibitor AS703569 is associated with inferior clinical outcome in multiple myeloma (MM), with promising anti‐MM activity of AS703569 demonstrated in preclinical studies in vitro and in vivo

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

Targeting BRAFV600E in thyroid carcinoma: therapeutic implications

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Targeting BRAF^V600E in thyroid carcinoma: therapeutic implications